The Role of Adjunctive Exenatide Therapy in Pediatric Type 1 Diabetes

• DOI: 10.2337/dc09-1959
• Publication Date: 2010-03-24T02:14:57Z
• Authors: Vandana S. Raman; Kimberly J. Mason; Luisa M. Rodriguez; Krishnavathana Ha...; Xiaoying Yu; Lisa Bomgaars; Rubina A. Heptulla
• Keywords: Adult; Blood Glucose; Male; Adolescent; Venoms; Postprandial Period; Drug Administration Schedule; 3. Good health; Young Adult; 03 medical and health sciences; Diabetes Mellitus, Type 1; 0302 clinical medicine; Double-Blind Method; Exenatide; Humans; Hypoglycemic Agents; Female; Child; Peptides; Original Research

OBJECTIVE Exenatide improves postprandial glycemic excursions in type 2 diabetes. could benefit 1 diabetes as well. We aimed to determine an effective and safe glucose-lowering adjuvant exenatide dose adolescents with RESEARCH DESIGN AND METHODS Eight subjects completed a three-part double-blinded randomized controlled study of premeal exenatide. Two doses (1.25 2.5 μg) were compared insulin monotherapy. Prandial was reduced by 20%. Gastric emptying hormones analyzed for 300 min postmeal. RESULTS Treatment both versus monotherapy significantly glucose over (P < 0.0001). administration failed suppress glucagon but delayed gastric 0.004). CONCLUSIONS Adjunctive therapy reduces hyperglycemia This reduction excursion occurs despite dose. suggest that has therapeutic potential adjunctive